Embla Medical posts $250 mln Q3 sales and narrows 2026 guidance
Embla Medical reported Q3 sales of $250 million, EBITDA of $56 million and net income of $26 million, and narrowed its 2026 outlook.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, Embla Medical hf booked third-quarter sales of $250 million, with EBITDA at $56 million and net income at $26 million. Gross margin reached 62%.
For 2026, the company narrowed its organic sales growth guidance to about 5%, down from the earlier 5-7% range. Its EBITDA margin before special items is now expected at about 21%, compared with the previous 20-22%.
why it matters
Narrower ranges point to greater clarity in the company's expectations for the full year. For investors this is more a sign of steady operating performance than a sharp change in momentum. The news concerns one company, so its wider market impact is limited.
market impact
Embla Medical: a narrower outlook reduces uncertainty around expectations for the company's shares
tags
instruments
sources
- Embla Medical Posts Q3 Sales At $250 Mln, Narrows Guidance — Reuters, 20 October 2026 at 05:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗